B+
Bull case
0%
Probability
Target price
$165.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
RVMD
Revolution MedicinesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
1%
Probability
Target price
$132.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+19.9
Score
AI commentary
Primary-source support is adequate for a cautious post-earnings monitoring view because the May 6 8-K confirms the Q1 results release and the 10-Q provides the operating and cash details. The follow-up evidence is still limited: the packet does not provide a concrete earnings surprise, guidance revision, or T+3 analyst revision set, and the peer set is generic for a concentrated RAS oncology developer. News tone remains helped by the prior daraxonrasib clinical update, but missing revision and market-reaction evidence should not be treated as positive confirmation.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction
Impact
tentative
Confidence
-
AI events
2026-06-30eventRASolve 308 Phase 3 initiation in first-line KRAS G12D NSCLC [#10-Q-2026-05-06]Medium impact
The 10-Q says Revolution expects to initiate RASolve 308, a Phase 3 registrational trial for zoldonrasib in first-line metastatic RAS G12D NSCLC, in the first half of 2026; actual initiation would support the broader RAS(ON) platform beyond daraxonrasib, but the memo should treat this as an execution checkpoint rather than a confirmed value inflection. [#10-Q-2026-05-06]
2026-12-31eventDaraxonrasib regulatory submission path after pivotal RASolute 302 win [#10-Q-2026-05-06]High impact
The Q1 filing says daraxonrasib's Phase 3 RASolute 302 showed median overall survival of 13.2 months versus 6.7 months for chemotherapy with a hazard ratio of 0.40, and management intends to use the dataset in a future NDA/CNPV pathway; regulatory filing progress is now the key de-risking event. [#10-Q-2026-05-06]
2026-12-31catalystQ1 cash runway improved, but burn and filing execution remain the post-earnings focus [#8-K-2026-05-06]Medium impact
Revolution's May 6 8-K confirms the company announced Q1 2026 financial results, and the Q1 filing shows $1.9 billion of cash, cash equivalents and marketable securities at quarter-end plus about $2.1 billion of net proceeds from April 2026 offerings. That funding supports multiple registrational programs, but Q1 net loss was $453.8 million and investors still need evidence that elevated daraxonrasib and zoldonrasib spend converts into filing, approval and launch progress. [#8-K-2026-05-06] [#10-Q-2026-05-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology